NRX:CC - Top 4 Spinal Injury Stocks for 2024 (NRX.V NVRO SYK BSX)
(NewsDirect)
Investors eyeingdynamic opportunities in healthcare should take note of the burgeoninggrowth anticipated in the spinal cord injury market. Projections forrobust advancements, driven by enhanced diagnosis and increased globalhealthcare spending, signal a lucrative trajectory from 2023 to 2032,with a significantly positive CAGR, according to Delveinsights.
With the spinal cord injury market showingpromising growth, let's explore key stocks that could offerpotential returns in the evolving healthcare landscape.
NurExone Biologic Inc. (TSXV: NRX)(FSE: J90) is positioned as a pioneering force inbiopharmaceuticals, with a primary focus on advancing the field ofbiologically-guided exosome therapy for traumatic spinal cordinjuries.
Founded on innovativetechnology, NurExone's flagship product, ExoPTEN, stands out as apotential game-changer. Administered intranasally, ExoPTEN representsa minimally invasive ExoTherapy designed to induce neuron regenerationand rewiring in traumatically damaged spinal cords. The company holdsexclusive worldwide licenses from the Technion and Tel AvivUniversity, signifying its leadership in translating groundbreakingconcepts into actionable solutions.
Key milestones in NurExone's journey include a notablePre-Investigational New Drug (Pre-IND) meeting with the U.S. Food andDrug Administration (FDA). This crucial interaction, held on August29, 2023, provided clear guidance for the manufacturing, preclinical,and clinical development plans of ExoPTEN. The FDA's endorsementof NurExone's proposed ExoPTEN release testing strategy andtoxicity study strategy sets the stage for submitting anInvestigational New Drug (IND) application by Q4 2024, with Phase 1/2human clinical studies anticipated to commence in 2025.
In tandem with its commitment to acutespinal cord injury treatments, NurExone secured a $1 million NewIsraeli Shekels grant from the Israel Innovation Authority. This grantfosters collaboration with Inteligex Inc. to develop an innovativehybrid therapy targeting chronic spinal cord injuries. Thecollaboration, approved by the Israel-Canada bilateral Eureka program,broadens NurExone's potential market focus.
The FDA's grant of Orphan-DrugDesignation (ODD) for ExoPTEN therapy on October 30, 2023, marks apivotal milestone. This designation recognizes the therapy'spotential impact on acute spinal cord injuries, offering NurExonesignificant benefits such as market exclusivity, financial incentives,and regulatory support. The ODD status streamlines the company'sgo-to-market strategy, signaling a promising path for ExoPTEN.
NurExone's commitment to continuousinnovation is evident in its laboratory tests unveiled on November 29,2023. These tests showcased two proprietary small inhibiting RNAsequences targeting the Peri-Neural Network (PNN) complex,representing a significant advancement in spinal cord injurytreatment. The potential for two new products in the company'sportfolio underscores NurExone's dedication to diversifying itsmolecular arsenal.
The company'sfinancial vitality received a boost with the closure of a non-brokeredprivate placement on January 5, 2024. Raising CAD$1,985,758.04, thisinvestment reflects strong investor confidence in NurExone'stechnology and direction. The proceeds are earmarked for advancingdevelopment activities, expanding the intellectual property portfolio,and supporting overall corporate objectives.
More recently, on January 17, 2024,NurExone's collaborative agreement with Inteligex Inc. wasofficially underway. This collaboration aims to combineInteligex's expertise in cell-based therapies with NurExone'sinnovative exosome platform, focusing on developing therapies forchronic spinal cord injuries. Additionally, NurExone has entered intoan agreement with bullVestor Medien GmbH to enhance awareness of itsproducts in German-speaking countries.
NurExone Biologic Inc. is at the forefront ofbiologically-guided exosome therapy, supported by a number ofmilestones and technological advancements. The journey from FDAinteractions to collaborative partnerships and financial investmentspaints a comprehensive picture of NurExone's trajectory,positioning the company as a leader in reshaping the landscape ofregenerative therapies for spinal cord injuries.
Nevro Corporation (NYSE: NVRO) ,headquartered in Redwood City, California, stands at the forefront ofthe medical device industry, specializing in transformative solutionsfor chronic pain treatment. Focused on their mission to alleviatedebilitating pain, Nevro developed the groundbreaking 10 kHzTherapy—an evidence-based, non-pharmacologic innovation that haspositively impacted over 100,000 patients worldwide.
One notable achievement is the publicationof 24-month data from the SENZA Nonsurgical Refractory Back Pain(NSRBP) trial in the Journal of Neurosurgery: Spine. This trialdemonstrated the profound benefits of Nevro's high-frequencyspinal cord stimulation (SCS) system in managing chronic back pain.Patients experienced significant pain relief, improved function, andenhanced quality of life, with a noteworthy reduction in opioidusage.
Moreover, Nevro'sstrategic acquisition of Vyrsa Technologies expands its portfolio toaddress chronic sacroiliac joint pain—an essential move in a marketvalued at over $2 billion and expected to witness double-digit growth.This acquisition positions Nevro to offer tailored therapies, drivinglong-term shareholder value and contributing to growth projections in2024.
The company's financialperformance, highlighted in the fourth-quarter 2023 results, exceededexpectations, showcasing consistent growth and a focus on key pillars:commercial execution, market penetration, and profit progress. Despitea restructuring initiative, Nevro remains committed to innovation, asevidenced by its partnership with Carelon Healthcare to broaden spinalcord stimulation coverage for painful diabetic neuropathy.
As Nevro continues to pioneer advancementsin chronic pain treatment, its comprehensive solutions and strategicinitiatives position it as a key player in the evolving landscape ofmedical device innovation.
Stryker Corporation (NYSE: SYK) , a trailblazer in themedical technology domain, recently achieved a historic milestone,surpassing $20 billion in annual sales for the first time in December2023. This achievement underscores Stryker's global impact on over130 million patients annually and solidifies its position as a majorleader in the medical device industry.
Specializing in MedSurg, Neurotechnology, Orthopaedics, andSpine, Stryker stands out for its commitment to innovation andimproving healthcare outcomes. In the realm of spine-relatedtechnology, the company's Spine division has demonstrated notableadvancements, showcasing a dedication to state-of-the-art solutionsfor surgeons and patients alike.
Robbie Robinson, President of the Spine division, emphasized thecompany's exciting year with multiple product launches,highlighting the continued growth of the Spine business. Among theselaunches, the Q Guidance System with Spine Guidance Software standsout, receiving the prestigious 2022 Best Technology in Spine award forits contributions to surgical spine planning and navigation.
Stryker's commitment to excellence isfurther evident in products like the Monterey AL Interbody System,incorporating Tritanium In-Growth Technology, and the Bone Mill+,designed for enhanced efficiency in bone milling. The OmniCurve curvedballoon system adds another dimension to Stryker's offerings,providing surgeons with advanced capabilities and control.
As Stryker achieves record-breakingfinancial success, its continuous innovation in spine-relatedtechnology positions the company as a key player with substantialpotential in the medical device sector. Stay tuned for more insightsinto Stryker's financial results during its upcoming Q4 andfull-year earnings call on January 30, 2024.
Boston Scientific (NYSE: BSX) , aglobal medical technology leader, has been at the forefront oftransforming lives through innovative medical solutions for over 40years. With a commitment to advancing science and addressing unmetpatient needs, the company provides high-performance solutions thatenhance healthcare outcomes.
In asignificant move, Boston Scientific recently completed the acquisitionof Relievant Medsystems Inc., marking a milestone in its chronic painportfolio. Relievant is renowned for its Intracept Intraosseous NerveAblation System, the only FDA-cleared therapy for vertebrogenic pain,a form of chronic low back pain. This acquisition strengthens BostonScientific's position in advanced interventional chronic paintreatments, offering physicians a comprehensive selection ofevidence-based options.
TheIntracept system utilizes basivertebral nerve ablation therapy and hasgarnered national coverage from major insurers like Anthem Blue CrossBlue Shield and Humana. These coverage expansions, along with existingagreements with Cigna Healthcare and local Medicare plans,significantly increase access to intracept treatments for over 150million lives.
Jim Cassidy,President of Neuromodulation at Boston Scientific, expressedenthusiasm about the revolutionary therapy's potential to helpmore people suffering from chronic pain. The acquisition, involving an$850 million upfront cash payment and additional contingent paymentsbased on sales performance, is poised to enhance BostonScientific's capabilities in addressing multiple paintargets.
This strategic movereflects Boston Scientific's commitment to offering physicians andpatients a diverse range of evidence-based treatment options, furthersolidifying its position as a leader in the evolving landscape ofchronic pain solutions.
Disclaimers: The Private SecuritiesLitigation Reform Act of 1995 provides investors a safe harbor inregard to forward-looking statements. Any statements that express orinvolve discussions with respect to predictions, expectations,beliefs, plans, projections, assumptions, objectives, goals, orassumptions of future events or performance are not statements ofhistorical fact may be forward looking statements. Forward lookingstatements are based on expectations, estimates, and projections atthe time the statements are made that involve a number of risks anduncertainties which could cause actual results or events to differmaterially from those presently anticipated. Forward lookingstatements in this action may be identified through use of words suchas projects, foresee, expects, will, anticipates, estimates, believes,understands, or that by statements, indicating certain actions "es; may, could or might occur Understand there is no guaranteepast performance is indicative of future results. Investing inmicro-cap or growth securities is highly speculative and carries anextremely high degree of risk. It is possible that an investor'sinvestment may be lost or due to the speculative nature of thecompanies profiled. Capital Gains Report (CGR), owned by RazorPitchInc., is responsible for the production and distribution of thiscontent. CGR is not operated by a licensed broker, a dealer, or aregistered investment advisor. It should be expressly understood thatunder no circumstances does any information published herein representa recommendation to buy or sell a security. CGR has been retained byAwareness Consulting to produce and distribute this content related toNRX. As part of that content, readers, subscribers, and webs areexpected to read the full disclaimers and financial disclosurestatement that can be found on our website capitalgainsreport.com Allcontent in this article is information of a general nature and doesnot address the circumstances of any particular individual or entity.Nothing in this article constitutes professional and/or financialadvice, nor does any information in the article constitute acomprehensive or complete statement of the matters discussed or thelaw relating thereto. CGR is not a fiduciary by virtue of any personsuse of or access to this content.
ContactDetails
CapitalGainsReport
MarkMcKelvie
+1 585-748-6862
Copyright (c) 2024 TheNewswire - All rights reserved.